Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection

Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection

<p><strong>Background</strong> The COVID-19 pandemic continues to be a worldwide threat and effective antiviral drugs and vaccines are being developed in a joint global effort. However, some elderly and immune-compromised populations are unable to raise an effective immune response...

Full description

Bibliographic Details
Main Authors:	Yue, D, Miah, KM, Habib, O, Meyer-Berg, H, Conway, CC, Viegas, MA, Dean, R, Satyapertiwi, D, Zhao, J, Wang, Y, Temperton, NJ, Gamlen, TPE, Gill, DR, Hyde, SC
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2022

Similar Items

Rapid determination of rSIV.F/HN lentiviral vector titre
by: Conway, CC, et al.
Published: (2020)

Improving the quantification of rSIV.F/HN vectors for cystic fibrosis gene therapy using droplet digital PCR
by: Gamlen, T, et al.
Published: (2020)

Large-scale, high-throughput production of rSIV.F/HN vectors
by: Viegas, MFA, et al.
Published: (2020)

Lung-targeting lentiviral vector for passive immunisation against influenza
by: Tan, TK, et al.
Published: (2020)

Intranasal lentiviral vector-mediated antibody delivery confers reduction of SARS-CoV-2 infection in elderly and immunocompromised mice
by: Du, Y, et al.
Published: (2022)

Type I interferon receptor signalling deficiency results in dysregulated innate immune responses to SARS-CoV-2 in mice
by: Ogger, PP, et al.
Published: (2022)

Gene therapy for surfactant protein B deficiency using recombinant AAV
by: Meyer-Berg, H, et al.
Published: (2019)

Emerging gene therapies for cystic fibrosis
by: Miah, K, et al.
Published: (2019)

Large-scale, high-throughput production of lentiviral vectors for multiple disease applications
by: Ashworth, R, et al.
Published: (2018)

597: Protocol development for mouse toxicology studies using lentiviral gene therapy
by: Sinadinos, A, et al.
Published: (2021)

Genomic diversity of SARS-CoV-2 in Oxford during United Kingdom’s first national lockdown
by: Munis, AM, et al.
Published: (2021)

Defining mechanisms of NOD2 receptor function in myeloid cells
by: Chapman, TPE
Published: (2017)

Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies
by: Joe James, et al.
Published: (2021-04-01)

Development of protocols for mouse GLP-toxicology studies
by: Sinadinos, A, et al.
Published: (2020)

Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies
by: Antepowicz, A, et al.
Published: (2016)

Antibody gene transfer for prophylaxis of respiratory syncytial virus (RSV) infection
by: Antepowicz, A, et al.
Published: (2018)

WHO international standard for SARS-CoV-2 antibodies to determine markers of protection
by: Zhu, F, et al.
Published: (2021)

Lentiviral-mediated expression of monoclonal antibodies in the lung to protect against influenza
by: Du, Y, et al.
Published: (2020)

431. Lung antibody factory for passive immunisation against influenza
by: Tan, T, et al.
Published: (2016)

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
by: Liu, C, et al.
Published: (2021)

Anti-spike protein to determine SARS-CoV-2 antibody levels: Is there a specific threshold conferring protection in immunocompromised patients?
by: Philippe Halfon, et al.
Published: (2023-01-01)

Assessment of the air-liquid interface culture model as a tool to validate efficacy of a rSIV.F/HN-CFTR vector
by: Sergijenko, A, et al.
Published: (2021)

Antibodies to SARS-CoV-2 are associated with protection against reinfection
by: Lumley, S, et al.
Published: (2020)

Antibody evasion by the P.1 strain of SARS-CoV-2
by: Dejnirattisai, W, et al.
Published: (2021)

The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
by: Daming Zhou, et al.
Published: (2024-03-01)

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant
by: Kevin K. Ariën, et al.
Published: (2022-03-01)

Low levels of CFTR gene transfer with F/HN pseudotyped lentivirus are sufficient to generate ion transport correction in airway cell cultures from cystic fibrosis patients
by: Sergijenko, A, et al.
Published: (2020)

Outliers Matter—Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies
by: Berthold Hocher, et al.
Published: (2022-10-01)

Single cell assays for quantifying MRNA and protein during cystic fibrosis gene therapy trials
by: Sinadinos, A, et al.
Published: (2020)

The probability of detection of SARS-CoV-2 in saliva
by: Thompson, RN, et al.
Published: (2020)

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
by: Dean Follmann, et al.
Published: (2023-06-01)

Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2
by: Wael Bahnan, et al.
Published: (2022-01-01)

Creating and destroying diaspora strategies
by: Gamlen, A
Published: (2011)

Creating and destroying diaspora strategies
by: Gamlen, A
Published: (2011)

Inelastic neutron scattering by adsorbed molecules and catalysts
by: Gamlen, P
Published: (1978)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
by: Alharbi, N, et al.
Published: (2017)

Identification of AAV serotypes for lung gene therapy in human embryonic stem cell-derived lung organoids
by: Meyer-Berg, H, et al.
Published: (2020)

Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
by: Huibin Lv, et al.
Published: (2020-06-01)

Compromised SARS-CoV-2-specific placental antibody transfer
by: Atyeo, Caroline, et al.
Published: (2021)

Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
by: Romain Rouet, et al.
Published: (2021-01-01)